Molecular Antibiotics, Current and Future Perspectives

Background: The development of molecular antibiotics has revolutionized the treatment of infectious diseases because they offer specific mechanisms of action which reduce side effects and slow the growth of antibiotic resistance compared to standard broad-spectrum antibiotics. The precise binding of these antibiotics to bacterial structures enhances their therapeutic effects. The ongoing development of molecular antibiotics has not solved the problem of antimicrobial resistance, which demands that scientists develop new antibiotic strategies. The current research investigates molecular antibiotics through a systematic review and meta-analysis to understand their mechanisms of action, resistance patterns, and potential new treatment methods. Methods: The current study followed PRISMA guidelines for its systematic search. The PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Google Scholar electronic databases were searched. Specific search strategy was used. 67 papers were included for qualitative synthesis, and 34 eligible studies were included for quantitative synthesis. The studies were published between 2015 to 2025. The current research evaluated studies that met specific inclusion criteria to extract data on molecular antibiotic classes, their resistance mechanisms, clinical performance, and drug development innovations. The research team conducted statistical analyses to evaluate treatment effectiveness and drug resistance patterns over the last 10 years. Results: The research demonstrates how molecular antibiotics have advanced through peptide-based treatments, CRISPR-Cas genome editing, and nanoparticle-based drug-delivery systems. Research studies demonstrate two main resistance mechanisms: efflux pumps and enzymes that break down new antibiotic compounds. The research indicates that AI-based drug development, when combined with combination therapy approaches, shows promise as a powerful tool to combat antibiotic resistance. Conclusion: The review demonstrates that global cooperation among healthcare providers, researchers, and policymakers is necessary to develop new molecular antibiotics for clinical use. The combination of innovative therapeutic methods with strategic drug development approaches makes molecular antibiotics powerful tools to fight bacterial infections while ensuring long-term treatment success.